Business Context and Reporting Period
Unicycive Therapeutics, Inc. filed a Form 8-K dated February 21, 2024, under Item 8.01, Other Events. The company is a development-stage biotechnology company whose common stock trades on the Nasdaq Capital Market under the symbol UNCY.
Key Financial and Liquidity Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial results.
Material Changes Versus the Prior Comparable Period
On February 21, 2024, Nasdaq notified the company that it had regained compliance with both applicable continued-listing requirements:
- The Minimum Market Value Requirement under Nasdaq Listing Rule 5550(b)(2), after previously falling below the $35 million threshold.
- The Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2), after previously having a closing bid price below $1.00 per share for 30 consecutive business days.
Nasdaq confirmed that both matters were closed.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. The principal disclosed risk was the company’s prior noncompliance with Nasdaq’s market-value and minimum-bid-price standards, which has been resolved as of the filing date. Continued listing remains subject to future compliance with Nasdaq requirements.
Investor Verification Items
- Verify the company’s ongoing compliance with Nasdaq’s market-value and minimum-bid-price requirements.
- Review subsequent filings for any new listing notices, reverse stock splits, or capital-raising activity that could affect share price and market capitalization.
- Consult the company’s financial filings for current cash balances, operating losses, liquidity needs, and financing risks, none of which are addressed in this 8-K.